Lavipharm

Lavipharm Inventory

The Inventory of Lavipharm (LAVI.AT) as of Nov 16, 2026 is 23.20 M EUR. In the previous year, Inventory was 20.76 M EUR — a change of 11.78% (higher).

Inventory

23.20 MEUR

YoY

11.78%

Last updated:

Inventory of Lavipharm is 2025 23.20 M EUR. Inventory of Lavipharm was 2024 20.76 M EUR. It decreases by 11.78% higher compared to the previous year.

The Lavipharm Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
4.90 M EUR
Jan 1, 2019
6.49 M EUR
Jan 1, 2020
8.42 M EUR
Jan 1, 2021
9.59 M EUR
Jan 1, 2022
10.91 M EUR
Jan 1, 2023
14.83 M EUR
Jan 1, 2024
20.76 M EUR
Jan 1, 2025
23.20 M EUR
The Lavipharm Inventory history
YEARInventoryYoY
23.20 MEUR+11.78%
20.76 MEUR+39.92%
14.83 MEUR+36.02%
10.91 MEUR+13.75%
9.59 MEUR+13.87%
8.42 MEUR+29.76%
6.49 MEUR+32.41%
4.90 MEUR-14.97%
5.76 MEUR-8.33%
6.29 MEUR+44.26%
4.36 MEUR+38.48%
3.15 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

Inventory of Lavipharm is 23.20 M EUR in 2025.

Inventory of Lavipharm changed from 20.76 M EUR to 23.20 M EUR, representing a 11.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Lavipharm since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Lavipharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lavipharm

All Key Metrics — Lavipharm